Please activate JavaScript!
Please install Adobe Flash Player, click here for download

2015|16 Annual Report Fraunhofer IGB - HUMAN IN VITRO BLOOD-BRAIN-BARRIER MODELS FOR DRUG DEVELOPMENT

81 Dipl.-Ing. (FH) Antje Appelt-Menzel Phone +49 931 31-80771 antje.appelt-menzel@igb.fraunhofer.de Dr. sc. hum. Marco Metzger Phone +49 931 31-86686 marco.metzger@igb.fraunhofer.de Contact Literature [1] Hawkins, B. T. et al. (2005) Pharmacological Reviews 57(2): 173–185 [2] Deli, M. A. et al. (2005) Cell Mol Neurobiol 25(1): 59–127 [3] Butt, A. M. et al. (1990) J Physiol 429: 47–62 [4] Crone, C. et al. (1982) Brain Res 241(1): 49–55 [5] Lippmann, E. S. et al. (2012) Nat Biotechnol 30(8): 783–791 [6] Lippmann, E. S. et al. (2014) Sci Rep 4: 4160 [7] Kola, I. et al. (2004) Nat Rev Drug Discov 3(8): 711–715. [8] Lippmann, E. S. et al. (2013) Fluids Barriers CNS 10(1): 2 Funding We would like to thank the German Federal Ministry of Educa- tion and Research (BMBF) for funding the project “BioTransporter ffi ienter irkstofftransport in biologischen ystemen yclo- dextrin-Komplexe zur Beschleunigung des Transportes lipophiler Wirkstoffe (LipoTrans)”, promotional reference 13N11803. improved due to co-culture cells with the result that we reach between cm2 and cm2 depending on the culture conditions. Outlook The application of stem cells has great potential for develop- ing regenerative therapies Thus, patient-specific hiP was used to establish in vitro disease models such as have been described earlier. Therefore, the hiPSC are differentiated into the above-mentioned cells that are affected by the disease but are difficult to access, in order to establish a sufficient number of models for the drug/medication tests. The pharmaceutical industry is searching for standardized and predictive model systems, since during the process of approval for drugs/medication many substances fail – due to toxicity and insufficient efficacy , even though they were previously tested in animal tests or cell lines [8]. 1 Staining of GLUT1+ transporter (A) and CL5+ tight junctions (B) in blood-brain barrier models. 2 Schematic depiction of the composition of in vitro blood-brain barrier models. membrane BBS-endothelial cells co-culture cells 2 Phone +4993131-80771 Phone +4993131-86686

Übersicht